Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug476 | BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM Wiki | 0.71 |
| drug4257 | Vitamins Wiki | 0.71 |
| drug2167 | Lopinavir/ Ritonavir Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 ratio. Chemoprophylaxis in this setting refers to the use of favipiravir for pre-exposure prophylaxis, post-exposure prophylaxis, pre-emptive therapy, or treatment for established COVID-19. This design mimics the approach to influenza outbreaks, which has proven efficacy for outbreak control. The primary outcome will be control of the outbreak, defined as no new microbiologically confirmed case of COVID-19 for 24 consecutive days up to day 40.
Description: Control of outbreak, defined as no new cases of COVID-19 in residents for 24 consecutive days up to day 40 after the start of prophylaxis
Measure: Control of Outbreak Time: Day 40Description: The proportion of residents of included LTCH units who die up to day 40, and up to day 60
Measure: Mortality (Residents) Time: Day 40, Day 60Description: The proportion of residents of included LTCH units who were uninfected at baseline and develop new symptomatic microbiologically confirmed COVID-19 up to day 40
Measure: COVID-19 Infection (Residents) Time: Day 40Description: The proportion of exposed staff uninfected at baseline in whom SARS-CoV-2 infection is identified up to day 14 and up to day 40
Measure: COVID-19 Infection (Staff) Time: Day 14, Day 40Description: The proportion of residents of included LTCH units hospitalized up to day 40
Measure: Hospitalization (Residents) Time: Day 40Description: The proportion of residents of included LTCH units who discontinue study medication due to adverse events
Measure: Medication Discontinuation (Residents) Time: Day 40Description: The proportion of LTCH staff of included LTCH units who discontinue study medication due to adverse events
Measure: Medication Discontinuation (Staff) Time: Day 40Description: The occurrence of new microbiologically confirmed COVID-19 infections in residents in other units of the LTCH up to day 40 (dichotomous, at LTCH level)
Measure: COVID-19 in new LTCH Units (a) Time: Day 40Description: The proportion of previously unaffected LTCH units of the remainder of the LTCH in which a case of COVID-19 is identified
Measure: COVID-19 in new LTCH Units (b) Time: Day 40Description: The proportion of residents in the remainder of the LTCH who develop COVID-19 infections up to day 40
Measure: COVID-19 in new LTCH Units (c) Time: Day 40The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with better outcome. Antiviral medications are most likely to be effective when administered soon after infection. There is therefore an urgent need to study subjects who have recently developed symptoms, or have recently been tested positive with or without symptoms, and who can be sampled frequently to understand changes in viral load. This cohort will allow us to collect detailed trajectory data on early disease and understand how pharmacological interventions may affect this. The objective of the FLARE trial is to assess whether early antiviral therapy with either favipiravir + Lopinavir/ritonavir (LPV/r), LPV/r or favipiravir is associated with a decrease in viral load compared with placebo. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.
Description: Quantitative polymerase chain reaction (PCR) performed on saliva samples at Day 5 of therapy
Measure: Upper respiratory tract viral load at Day 5 Time: Day 5 from randomisationDescription: Quantitative polymerase chain reaction (PCR) performed on saliva samples at Day 5 of therapy
Measure: Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy Time: 5 days from randomisationDescription: Quantitative polymerase chain reaction (PCR) performed on stool samples at Day 7 and Day 14 post-randomisation
Measure: Proportion of participants with undetectable stool viral load after 7 days of therapy and 14 days post-randomisation Time: Day 7 and Day 14 from randomisationDescription: PCR performed on daily saliva samples collected between Day 1 and Day 7 post-randomisation
Measure: Rate of decrease in upper respiratory tract viral load during 7 days of therapy Time: 7 daysDescription: Daily body temperature records between Day 1 and Day 7 post-randomisation
Measure: Duration of fever following commencement of medication Time: 7 daysDescription: Standard diagnostic laboratory assays for liver transaminases, alkaline phosphatase and bilirubin
Measure: Proportion of participants with hepatotoxicity after 7 days of therapy and 14 days post-randomisation Time: Day 7 and Day 14 from randomisationDescription: Determination of medication-related adverse events by investigators at Day 7 and Day 14 post-randomisation
Measure: Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation Time: Day 7 and Day 14 from randomisationDescription: Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation
Measure: Proportion of participants admitted to hospital with COVID-19 related illness Time: 28 daysDescription: Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation
Measure: Proportion of participants admitted to ICU with COVID-19 related illness Time: 28 daysDescription: Participant self-report, review of hospital records and discharge summaries within 28 days of randomisation
Measure: Proportion of participants who have died with COVID-19 related illness Time: 28 daysDescription: Assess pharmacokinetics of favipiravir as measured by Clearance (CL)
Measure: Pharmacokinetics of favipiravir as measured by Clearance (CL) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Volume of distribution (V)
Measure: Pharmacokinetics of favipiravir as measured by Volume of distribution (V) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)
Measure: Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)
Measure: Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)
Measure: Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)
Measure: Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke) Time: Day 7 from randomisationDescription: Assess pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)
Measure: Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf) Time: Day 7 from randomisationDescription: Assess pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)
Measure: Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta) Time: Day 7 from randomisationDescription: Assess pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)
Measure: Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax) Time: Day 7 from randomisationDescription: Assess pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)
Measure: Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50) Time: Day 7 from randomisationDescription: Deep sequencing of virus and bioinformatic analysis
Measure: Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment Time: Day 7 from randomisationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports